Telix Pharmaceuticals
6 hedge funds and large institutions have $799K invested in Telix Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
1,290% more capital invested
Capital invested by funds: $57.4K → $799K (+$741K)
500% more funds holding
Funds holding: 1 → 6 (+5)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
ABC Arbitrage
Paris,
France
|
+$471K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$177K |
| 3 |
Morgan Stanley
New York
|
+$98.4K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$20K |
| 5 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$2.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.38K |
TLX Hedge Fund Activity: Q1 2025 in Review
6 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q1 2025, worth a combined $799K — up 1,290% from $57.4K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TLX positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was ABC Arbitrage, opening a new position worth an estimated $471K. The largest seller was UBS Group, cutting an estimated $1.38K.
- 6 institutional investors held Telix Pharmaceuticals (TLX) as of Q1 2025, up from 1 in Q4 2024.
- Funds reported $799K of Telix Pharmaceuticals stock for Q1 2025, up 1,290% quarter-over-quarter.
- 5 funds opened new Telix Pharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +5 holders.
- The largest Telix Pharmaceuticals buyer in Q1 2025 was ABC Arbitrage, an estimated $471K added.
- The largest Telix Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $1.38K sold.
Based on aggregated 13F filings for Q1 2025.